Authors:
SLAYTER KL
LUDWIG EA
LEW KH
MIDDLETON E
FERRY JJ
JUSKO WJ
Citation: Kl. Slayter et al., ORAL-CONTRACEPTIVE EFFECTS ON METHYLPREDNISOLONE PHARMACOKINETICS ANDPHARMACODYNAMICS, Clinical pharmacology and therapeutics, 59(3), 1996, pp. 312-321
Authors:
JUSKO WJ
MILAD MA
LUDWIG EA
LEW KH
KOHLI RK
Citation: Wj. Jusko et al., METHYLPREDNISOLONE PHARMACOKINETICS AND PHARMACODYNAMICS IN CHRONIC-RENAL-FAILURE, Clinical nephrology, 43, 1995, pp. 16-19
Authors:
SLAYTER KL
LUDWIG EA
LEW KH
MIDDLETON E
FERRY JJ
JUSKO WJ
Citation: Kl. Slayter et al., ORAL-CONTRACEPTIVE EFFECTS ON METHYLPREDNISOLONE PHARMACOKINETICS ANDPHARMACODYNAMICS, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 182-182
Citation: Kh. Lew et Wj. Jusko, PHARMACODYNAMIC MODELING OF CORTISOL SUPPRESSION FROM FLUOCORTOLONE, European Journal of Clinical Pharmacology, 45(6), 1993, pp. 581-583
Authors:
LEW KH
LUDWIG EA
MILAD MA
DONOVAN K
MIDDLETON E
FERRY JJ
JUSKO WJ
Citation: Kh. Lew et al., GENDER-BASED EFFECTS ON METHYLPREDNISOLONE PHARMACOKINETICS AND PHARMACODYNAMICS, Clinical pharmacology and therapeutics, 54(4), 1993, pp. 402-414